Q1 2024 Arbutus Biopharma Corp Earnings Call Transcript
Key Points
- Arbutus Biopharma Corp (ABUS) has initiated patient screening in their third Phase 2a clinical trial, AB-729-203, evaluating induceran in combination with durvalumab, an anti-PD-L1 monoclonal antibody.
- The company reported preliminary data from the AB-101-001 Phase 1a/1b clinical trial, showing AB-101 is generally well tolerated with evidence of dose-dependent receptor occupancy.
- Arbutus Biopharma Corp (ABUS) ended the first quarter of 2024 with approximately $138 million in cash, cash equivalents, and investments, providing a strong financial position to advance their mission.
- Two abstracts, including data from Phase 2a clinical trials, were accepted for presentation at the EASL Congress, indicating recognition in the scientific community.
- The company has a robust pipeline with multiple ongoing clinical trials aimed at developing a functional cure for chronic HBV, leveraging their proprietary clinical assets.
- The retirement of Co-Founder and Chief Scientific Officer, Dr. Mike Sofia, could impact the continuity and leadership within the company's scientific team.
- Arbutus Biopharma Corp (ABUS) is still in the early stages of clinical trials for several of their key assets, which means commercial viability and regulatory approval are still uncertain.
- The company anticipates a net cash burn ranging from $63 million to $67 million for 2024, highlighting significant ongoing operational expenses.
- The ongoing patent infringement lawsuit against Moderna involves uncertainties and potential financial liabilities depending on the outcome.
- Arbutus Biopharma Corp (ABUS) faces intense competition in the HBV treatment market, which could impact the adoption and success of their products if they reach the market.
Good day, and thank you for standing by, and welcome to the Arbutus Biopharma 2024 First Quarter Financial Results and Corporate Update Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would now like to hand the conference over to your first speaker today, Lisa Caperelli, Vice President of Investor Relations. Please go ahead.
Thank you, Andrea. Good morning, everyone. And thank you for joining Arbutus' First Quarter 2024 Financial Results and Corporate Update Call. Joining me today from the Arbutus executive team are Mike McElhaugh, Interim President and Chief Executive Officer; Dr. Karen Sims, Chief Medical Officer; David Hastings, Chief Financial Officer; and Dr. Mike Sofia, Chief Scientific Officer. Mike McElhaugh will begin with a corporate update, followed by Karen, who will review our ongoing clinical programs. Dave will then provide a review of the company's first quarter 2024 financial results. After our prepared
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
